Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGX 148

Next Previous
Drug Profile

AGX 148

Alternative Names: AGX-148

Latest Information Update: 14 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AgonOx; SQZ Biotech
  • Developer AgonOx; Phio Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin 2 replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma; Solid tumours

Most Recent Events

  • 05 Apr 2024 Interim efficacy and adverse events data from a phase I trial in solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 15 Jun 2023 Phase-I clinical trials in Malignant melanoma (In adults, In the elderly, Late-stage disease, Second-line therapy or greater, Monotherapy) in USA (IV) (NCT05902520)
  • 15 Jun 2023 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease, Second-line therapy or greater, Monotherapy) in USA (IV) (NCT05902520)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top